ISPOR 5th Asia-Pacific Conference - Released Presentations
 
RELEASED PRESENTATIONS


PLENARY SESSIONS
 
FIRST PLENARY SESSION:
Health Technology Assessment in the Significantly Evolving Health Care Systems in Asia

Health Technology Assessment in the Significantly Evolving Health Care Systems in Asia
Chee-Jen Chang, PhD, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan

Development and Challenge to HTA in China
Jie Chen, PhD, Director, Key Lab of Health Technology Assessment, Ministry of Health, Director, Center for Health Technology Assessment, Shanghai Municipal Bureau and Professor, School of Public Health, Fudan University, Shanghai, China

Health Technology Assessment in Significantly Evolving Health Care Systems in Asia - Commentary
Manny Papadimitropoulos, PhD,
Director, Emerging Markets HTA, Eli Lilly and Company, Toronto, ON, Canada


SECOND PLENARY SESSION:
Involving Patients & Health Care Practitioners in Health Care Decisions: Learning From Each Other

Involving Patients and Professionals at NICE
Sir Andrew Dillon, Chief Executive, the National Institute for Health and Clinical Excellence (NICE), London, UK

Involving Patients in HTA Decision-Making: Lessons Learned
Durhane Wong-Rieger, PhD, Chair, International Alliance of Patients' Organizations, London, UK

Involving Patients and Healthcare Practitioners in Health care Decisions
Stephen Mason, LLB, BComm, DipCM, FCPA, FCSA , JP, Chief Executive Officer, the Australian Patients Association, Melbourne, VIC, Australia

Patient and Public Involvement in Healthcare Decision-making
Tae-jin Lee, PhD, Associate Professor, School of Public Health, Seoul National University, Seoul, South Korea


THIRD PLENARY SESSION:
Challenges of Adopting New Innovative Technologies in Health Care Coverage Decision-Making in Asia

Challenges of Adopting New Innovative Technologies in Health Care Decision-Making in Asia
Bong-min Yang, PhD, Professor of Health Economics, School of Public Health, Seoul National University, Seoul, South Korea

Indonesian Health Care System, Policy and The Road to Universal Health Coverage
Hasbullah Thabrany, MD, PhD, MPH, Professor, Faculty of Public Health, University of Indonesia, Depok, Indonesia

Adopting New Innovative Technologies in Health Care Coverage Decision-Making in Asia
Jianwei Xuan, PhD, MD, Senior Director & Asia Lead, Outcomes Research & Emerging Markets, Pfizer Inc., New York, NY, USA


PODIUM AND POSTER PRESENTATIONS
 

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 5th Asia-Pacific Conference, see: ISPOR Outcomes Research Digest an electronic database of over 20,000 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 5th Asia-Pacific Conference - Taipei, Taiwan, 2012
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.

 WORKSHOP PRESENTATIONS

(Presentations to be added pending speaker approval)

 
W1: USING INDIVIDUAL SIMULATION TO FORECAST DISEASE EPIDEMIOLOGY AND BURDEN OF ILLNESS

Why Modeling Is Needed for Estimating Disease Burden?
John Cai, PhD, Professor, China Europe International Business School, Shanghai, China

 
W2: INTEGRATION OF SURVIVAL WITH QUALITY OF LIFE FOR OUTCOMES RESEARCH: SHARING OF A FREE SOFTWARE

Integration of survival with quality of life for outcomes research: sharing of a software
Jing-Shiang Hwang, PhD
, Deputy Director, Institute of Statistical Science, Academia Sinica, Taipei, Taiwan

Integration of quality of life and survival for outcome evaluation and policy decision in health care services
Jung-Der Wang, MD, ScD, Professor & Chair, Department of Public Health, National Cheng Kung University College of Medicine, Tainan, Taiwan

 
W3: ISSUES IN ADAPTING GLOBAL HEALTH ECONOMIC MODELS TO EMERGING MARKETS: A CONVERSATION WITH HEALTH AUTHORITIES, PHARMACEUTICAL INDUSTRY AND CONSULTANTS IN ASIA PACIFIC
Renee J.G. Arnold, PharmD, RPh, Principal, HEOR, IMS Health, New York, NY, USA; Jianwei Xuan, MD, PhD, Senior Director & Team Leader, Pfizer, New York, NY, USA
 
W4: CONDUCTING ONCOLOGY HEALTH SERVICES RESEARCH AND COMPARATIVE EFFECTIVENESS RESEARCH USING LARGE CLAIM DATABASES: TAIWANESE AND UNITED STATES EXPERIENCES

Fei-Yuan Hsiao, PhD, Assistant Professor, Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan; Ya-Chen Tina Shih, PhD, Associate Professor, Section of Hospital Medicine, Department of Medicine and Director, Program in the Economics of Cancer, The University of Chicago, Chicago, IL, USA; Chun-Ru Chien, PhD, MD, Director, China Medical University Hospital, Taichung, Taiwan; C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA

 
W6: EVALUATING EVIDENCE FOR MEDICAL DEVICES – INTERNATIONAL EXPERIENCES
Yen-Fu Chen, MSc, MPH, PhD, Research Fellow, Department of Public Health, Epidemiology and Biostatistics, University of Birmingham, Edgbaston, Birmingham, UK; Jasmine Raoh-Fang Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan
 
W7: REALITIES OF POPULATING GLOBAL MODELS IN ASIA

Realities in Populating Global Models in Asia
Soraya Azmi, MBBS, MPH, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Selangor, Malaysia

The View Through One End of the Kaleidoscope
Kathleen Yeoh, BSc, (Hons), Government Affairs & Market Access Manager, Bayer HealthCare Pharmaceuticals, Bayer Co. (Malaysia) Sdn. Bhd., Petaling Jaya, Selangor, Malaysia

 
W8: ONE SIZE FITS ALL? ADAPTING GLOBAL MODELS FOR LOCAL NEEDS
Andrew H. Briggs, DPhil, MSc, William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Tracy A. Comans, PhD, Research Fellow, Centre for Applied Health Economics, Griffith University, Meadowbrook, Queensland, Australia; Jasmine Raoh-Fang Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan
 
W12: DECISION MAKING IN HEALTH TECHNOLOGY ASSESSMENT

Olivia Wu, PhD, Reader in Health Economics, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK; Neil Hawkins, PhD, Vice President, Health Economics, Oxford Outcomes, Oxford, UK; Jasmine Raoh-Fang Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan

 
ISSUE PANEL PRESENTATIONS

(Presentations to be added pending speaker approval)


IP1: How to harmonize HTA and Value for innovation?

Sang-Il Lee, PhD, MD, MPH, President, Korea Association of Health Technology Assessment (KAHTA), University of Ulsan College of Medicine, Seoul, South Korea; Mi-Hai Park, PhD, Research Fellow, Health Insurance Review and Assessment Service, Seoul, South Korea; Su-Kyoung Ko, PhD, Market Access Director, Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea;  Eui Kyung Lee, PhD, Professor of Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Sungkyunkwan University, Seoul, South Korea; Jeonghoon Ahn, PhD, MA, Senior Director, Office of Health Services Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

 
IP2: PERSONALIZED MEDICINE: HOW CAN WE GO WITH IT?

Personalised medicine
Philippa Delahoy, PhD
, Senior Therapeutic Area Manager, Pfizer Australia, Sydney, Australia

 
IP3: CHALLENGES IN IMPLEMENTING THE 4TH HURDLE IN CHINA

Challenges in Implementing the 4th Hurdle in China
Seng Chuen Tan, MSc, Director, Double Helix Consulting, Asia-Pacific, Singapore, Singapore; Yan Yan Wang, MSc, Assistant Researcher, National Social Security Institute, Ministry of Human Resources and Social Security, Beijing, China

 
IP4: USING MAPPED EQ-5D FROM DISEASE-SPECIFIC MEASURES IN COST-UTILITY ANALYSIS: WHAT IS THE CURRENT STATE IN ASIA PACIFIC?
Jittrakul Leartsakulpanitch, PhD, Director, Market Access, Asia Pacific, Johnson & Johnson Asia Pacific, Bangkok, Thailand; Chiun-Fang Chiou, PhD, Director, Patient Reported Outcomes, Janssen Global Services, LLC, West Hills, CA, USA
 
IP5: DOES PRICE DISCRIMINATION HAVE A PLACE IN PHARMACEUTICAL PRICING IN ASIA?
Adèle R. Weston, PhD, Vice President & Senior Scientist, OptumInsight, Lilyfield, NSW, Australia; Mendel Grobler, MBA, Director, Access and Patient Affairs, Pfizer Australia, West Ryde, NSW, Australia; Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
EDUCATIONAL SYMPOSIA

(Presentations to be added pending symposia host approval)

 
HEALTH ECONOMICS AND OUTCOMES RESEARCH IN PERSONALIZED MEDICINE
(Sponsored by Pfizer)
Boxiong Tang, MD, PhD, Senior Director, Outcomes Research, Emerging Markets, Pfizer Inc., New York, NY, USA; Yen-Huei Tarn, PhD, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan; Lou Garrison, PhD, Professor, Department of Pharmacy, Washington University, Seattle, WA, USA; Jianwei Xuan, MD, PhD, Senior Director, Outcomes Research, Emerging Markets, Pfizer Inc., New York, NY, USA
 
INNOVATION: WHAT IS IT, WHO SHOULD PAY AND WHAT IS A FAIR PRICE?
(Sponsored by GlaxoSmithKline)
David Dankó, MSc, PhD, Research Leader, Doctoral School of Management, Corvinus University of Budapest, Budapest, Hungary; Raoh-Fang (Jasmine) Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation & Adjunct Assistant Professor, Taipei Medical University, Taipei, Taiwan; Speaker: Jeremy Lim, MBBS, MPH, MRCS (Edin), MMed (Surg), FAMS, CEO, Fortis Colorectal Hospital, Singapore
 
CLINICAL ENDPOINTS: FINAL VERSUS SURROGATE ENDPOINT - IMPLICATIONS AND RELEVANCE FROM A PAYER, PHYSICIAN AND PATIENT PERSPECTIVE
(Sponsored by Eli Lilly and Company)
Bong-Min Yang, PhD, Professor, School of Public Health, Seoul National University, Seoul, South Korea; Raoh-Fang (Jasmine) Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation & Adjunct Assistant Professor, Taipei Medical University, Taipei, Taiwan; Gilberto de Lima Lopes, Jr., MD, MBA, FAMS, Senior Consultant in Medical Oncology and Assistant Director for Clinical Research & Assistant Professor of Oncology, Johns Hopkins Singapore International Medical Centre, Johns Hopkins University School of Medicine, Singapore; John Stubbs, Executive Officer, Cancer Voices Australia, Glebe, Australia

 


5th Asia-Pacific Conference Main Page